Argenx discovers, designs and develops innovative antibody therapeutics for its own pipeline of treatments for cancer and autoimmune diseases and for its partners. Harnessing our technology and know-how, we aim to meet the needs of patients by engineering antibodies to target diseases too complex for other antibody technologies.
argenx to Present at Upcoming Investor Conferences Mon, 13 Nov 2017 06:02:01 +0000 November 13, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies ...
argenx announces results of extraordinary shareholders' meeting 2017 Tue, 07 Nov 2017 11:02:02 +0000 November 7, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies ...
argenx launches Phase I trial with subcutaneous formulation of ARGX-113 Mon, 30 Oct 2017 06:02:01 +0000 Subcutaneous formulation intended for chronic therapy setting October 30, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing ...
argenx reports third quarter 2017 financial results and provides business update Thu, 26 Oct 2017 05:05:18 +0000 Breda, the Netherlands/ Ghent, Belgium argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases ...
Invitation to the extraordinary shareholders' meeting Fri, 22 Sep 2017 10:50:15 +0000 September 22, 2017 Breda, the Netherlands/ Ghent, Belgium- argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe ...
argenx reports second quarter business update and half-year 2017 financial results Thu, 24 Aug 2017 05:02:01 +0000 Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT August 24, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.